Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
暂无分享,去创建一个
[1] W. Löscher,et al. Immunohistochemical Localization of P-glycoprotein in Rat Brain and Detection of Its Increased Expression by Seizures Are Sensitive to Fixation and Staining Variables , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[2] W. Löscher,et al. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures , 2004, Neuroscience.
[3] D. Horrobin,et al. Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression. , 2004, The international journal of neuropsychopharmacology.
[4] W. Löscher,et al. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats , 2004, Neuroreport.
[5] W. Löscher,et al. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions , 2004, Nature Medicine.
[6] K. Yamada,et al. St. John's Wort (Hypericum perforatum) induces overexpression of multidrug resistance protein 2 (MRP2) in rats: a 30-day ingestion study. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[7] S. A. Thomas,et al. Anti-HIV drug distribution to the central nervous system. , 2004, Current pharmaceutical design.
[8] S. Cisternino,et al. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. , 2004, Cancer research.
[9] J. C. Baayen,et al. Expression and Cellular Distribution of Multidrug Resistance–related Proteins in the Hippocampus of Patients with Mesial Temporal Lobe Epilepsy , 2004, Epilepsia.
[10] R. Kerwin,et al. Do antidepressants regulate how cortisol affects the brain? , 2004, Psychoneuroendocrinology.
[11] D. Begley,et al. ABC transporters and the blood-brain barrier. , 2004, Current pharmaceutical design.
[12] G. Fricker,et al. Modulation of Drug Transporters at the Blood-Brain Barrier , 2004, Pharmacology.
[13] A. M. George,et al. The ABC transporter structure and mechanism: perspectives on recent research , 2004, Cellular and Molecular Life Sciences CMLS.
[14] C. Tirolo,et al. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[15] W. Löscher,et al. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats , 2004, Epilepsy Research.
[16] C. L. Graff,et al. Drug transport at the blood-brain barrier and the choroid plexus. , 2004, Current drug metabolism.
[17] S. Cole,et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.
[18] W. Löscher,et al. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats , 2004, Epilepsy Research.
[19] C. L. Graff,et al. Variable modulation of opioid brain uptake by P-glycoprotein in mice. , 2004, Biochemical pharmacology.
[20] A. Walmsley,et al. Structure and function of efflux pumps that confer resistance to drugs. , 2003, The Biochemical journal.
[21] Y. Sheline,et al. Psychiatric comorbidity, health, and function in epilepsy , 2003, Epilepsy & Behavior.
[22] W. Löscher,et al. Brain Access and Anticonvulsant Efficacy of Carbamazepine, Lamotrigine, and Felbamate in ABCC2/MRP2‐Deficient TR− Rats , 2003, Epilepsia.
[23] W. Pardridge,et al. P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. , 2003, Neuroreport.
[24] B. Dijkmans,et al. Multidrug resistance proteins in rheumatoid arthritis, role in disease‐modifying antirheumatic drug efficacy and inflammatory processes: an overview , 2003, Scandinavian journal of rheumatology.
[25] S. Choudhuri,et al. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[26] M. Fromm,et al. Importance of P‐glycoprotein for drug disposition in humans , 2003, European journal of clinical investigation.
[27] L. Martinian,et al. Major Vault Protein, a Marker of Drug Resistance, Is Upregulated in Refractory Epilepsy , 2003, Epilepsia.
[28] L. Doyle,et al. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.
[29] F. Holsboer,et al. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption , 2003, Biological Psychiatry.
[30] P. L. Golden,et al. Blood-brain barrier efflux transport. , 2003, Journal of pharmaceutical sciences.
[31] R. Kim. Drug transporters in HIV Therapy. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[32] W. Löscher,et al. Multidrug Resistance Protein MRP2 Contributes to Blood-Brain Barrier Function and Restricts Antiepileptic Drug Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[33] H. Galla,et al. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood–brain barrier , 2003, Brain Research.
[34] E. Aronica,et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors , 2003, Neuroscience.
[35] D. Janigro,et al. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. , 2003, Current drug targets.
[36] D. Goldstein,et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.
[37] S. Sisodiya. Mechanisms of antiepileptic drug resistance , 2003, Current opinion in neurology.
[38] Christian E Elger,et al. A novel mechanism underlying drug resistance in chronic epilepsy , 2003, Annals of neurology.
[39] W. Haefeli,et al. Inhibition of P-Glycoprotein by Newer Antidepressants , 2003, Journal of Pharmacology and Experimental Therapeutics.
[40] H. Coley,et al. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[41] N. Shaik,et al. Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.
[42] A. Schinkel,et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.
[43] D. Binder. Mechanisms of drug resistance in epilepsy: lessons from oncology. London, United Kingdom, 13-15 March 2001. Symposium proceedings. , 2002, Novartis Foundation symposium.
[44] M. Barrand,et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.
[45] Armin Buschauer,et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. , 2002, The Journal of clinical investigation.
[46] Wolfgang Löscher,et al. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy , 2002, Epilepsy Research.
[47] W. Löscher,et al. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. , 2002, European journal of pharmacology.
[48] M. Vore,et al. Regulation of Expression of the Multidrug Resistance-Associated Protein 2 (MRP2) and Its Role in Drug Disposition , 2002, Journal of Pharmacology and Experimental Therapeutics.
[49] J. Hirrlinger,et al. Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones , 2002, Journal of neurochemistry.
[50] E. Aronica,et al. Limbic Seizures Induce P-Glycoprotein in Rodent Brain: Functional Implications for Pharmacoresistance , 2002, The Journal of Neuroscience.
[51] P. McNamara,et al. GF120918, a P-Glycoprotein Modulator, Increases the Concentration of Unbound Amprenavir in the Central Nervous System in Rats , 2002, Antimicrobial Agents and Chemotherapy.
[52] R. Béliveau,et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.
[53] A. Neyfakh. Mystery of multidrug transporters: the answer can be simple , 2002, Molecular microbiology.
[54] Wolfgang Löscher,et al. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. , 2002, The Journal of pharmacology and experimental therapeutics.
[55] R. Upton,et al. Theoretical Aspects of P-glycoprotein Mediated Drug Efflux on the Distribution Volume of Anaesthetic-related Drugs in the Brain , 2002, Anaesthesia and intensive care.
[56] Terry R Stouch,et al. Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.
[57] W. Löscher. Current status and future directions in the pharmacotherapy of epilepsy. , 2002, Trends in pharmacological sciences.
[58] N. Russell,et al. P-glycoprotein in Acute Myeloid Leukaemia: Therapeutic Implications of its Association With Both a Multidrug-resistant and an Apoptosis-resistant Phenotype , 2002, Leukemia & lymphoma.
[59] J. Drewe,et al. By-passing of P-glycoprotein Using Immunoliposomes , 2002, Journal of drug targeting.
[60] M. Mayberg,et al. Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy , 2001, Epilepsia.
[61] R. Bendayan,et al. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.
[62] W. Löscher,et al. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain , 2001, Neuroreport.
[63] W. Löscher,et al. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain , 2001, Neuroreport.
[64] A. Sartorelli,et al. Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. , 2001, Biochemical and biophysical research communications.
[65] T. Druley,et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.
[66] D. Breimer,et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier , 2001, AIDS.
[67] G. Pasternak,et al. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs , 2001, Nature Neuroscience.
[68] U. Brinkmann,et al. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. , 2001, Pharmacogenomics.
[69] M. Thom,et al. Multidrug-resistance protein 1 in focal cortical dysplasia , 2001, The Lancet.
[70] W. Elmquist,et al. Microdialysis in the study of drug transporters in the CNS. , 2000, Advanced drug delivery reviews.
[71] J. Drewe,et al. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. , 2000, Molecular pharmacology.
[72] W Vaalburg,et al. The blood-brain barrier and oncology: new insights into function and modulation. , 2000, Cancer treatment reviews.
[73] Donald W. Miller,et al. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells , 2000, Brain Research.
[74] S. R. Harris,et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[75] L. Ratner,et al. Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.
[76] M. Kool,et al. A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.
[77] G. Pollack,et al. Morphine Antinociception Is Enhanced in mdr1a Gene-Deficient Mice , 2000, Pharmaceutical Research.
[78] J. Laplanche,et al. Functional expression of p‐glycoprotein and multidrug resistance‐associated protein (mrp1) in primary cultures of rat astrocytes , 2000, Journal of neuroscience research.
[79] C. Bernards,et al. Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein , 2000, Anesthesiology.
[80] W. Pardridge,et al. Brain Microvascular P-Glycoprotein and a Revised Model of Multidrug Resistance in Brain , 2000, Cellular and Molecular Neurobiology.
[81] F. Holsboer,et al. Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption , 2000, Neuropsychopharmacology.
[82] A. Seelig,et al. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. , 2000, International journal of clinical pharmacology and therapeutics.
[83] P. Kwan,et al. Early identification of refractory epilepsy. , 2000, The New England journal of medicine.
[84] D D Breimer,et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. , 2000, The Journal of clinical investigation.
[85] M. Fromm,et al. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. , 2000, International journal of clinical pharmacology and therapeutics.
[86] M. Kool,et al. The multidrug resistance protein family. , 1999, Biochimica et biophysica acta.
[87] S. Sisodiya,et al. Over-expression of P-glycoprotein in malformations of cortical development. , 1999, Neuroreport.
[88] A. G. de Boer,et al. The role of P‐glycoprotein in blood‐brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice , 1999, British journal of pharmacology.
[89] A. Rabinowicz,et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. , 1999, Pediatric neurology.
[90] C. Beglinger,et al. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[91] J. Hellewell,et al. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. , 1999, The Journal of clinical psychiatry.
[92] K. Brouwer,et al. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[93] W. Ong,et al. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections , 1999, Experimental Brain Research.
[94] A. Schinkel,et al. P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.
[95] G. Regesta,et al. Clinical aspects and biological bases of drug-resistant epilepsies , 1999, Epilepsy Research.
[96] A. Sartorelli,et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[97] W. Pardridge,et al. P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries , 1999, Brain Research.
[98] C. Nemeroff,et al. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. , 1998, The Psychiatric clinics of North America.
[99] R. Vonk,et al. Impaired activity of the bile canalicular organic anion transporter (Mrp2/cmoat) is not the main cause of ethinylestradiol‐induced cholestasis in the rat , 1998, Hepatology.
[100] D. Roden,et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.
[101] P. Carvey. Drug Action in the Central Nervous System , 1998 .
[102] U. Bickel,et al. Brain Microvascular and Astrocyte Localization of P‐Glycoprotein , 1997, Journal of neurochemistry.
[103] M. Fava,et al. Definition and epidemiology of treatment-resistant depression. , 1996, The Psychiatric clinics of North America.
[104] N. Barbaro,et al. MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy , 1995, Epilepsia.
[105] M C Willingham,et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[106] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[107] W. Lasoń. [Mechanisms of drug resistance in epilepsy]. , 2006, Przeglad lekarski.
[108] Jiunn H Lin,et al. How significant is the role of P-glycoprotein in drug absorption and brain uptake? , 2004, Drugs of today.
[109] T. Fojo,et al. Reversal of multidrug resistance: lessons from clinical oncology. , 2002, Novartis Foundation symposium.
[110] M Thom,et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. , 2002, Brain : a journal of neurology.
[111] G. Scheffer,et al. Drug resistance molecules: lessons from oncology. , 2002, Novartis Foundation symposium.
[112] W. Löscher. Animal models of drug-resistant epilepsy. , 2002, Novartis Foundation symposium.
[113] D. Begley,et al. Drug resistance in epilepsy: the role of the blood-brain barrier. , 2002, Novartis Foundation symposium.
[114] B. McEwen,et al. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.
[115] W. Pardridge. Blood-brain barrier biology and methodology. , 1999, Journal of neurovirology.
[116] J. Silverman. Multidrug-resistance transporters. , 1999, Pharmaceutical biotechnology.
[117] A. Seelig. How does P-glycoprotein recognize its substrates? , 1998, International journal of clinical pharmacology and therapeutics.
[118] R. Duncan,et al. Epilepsy and the blood-brain barrier. , 1991, British journal of hospital medicine.
[119] M. Melamed,et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[120] W. Oldendorf,et al. Epilepsy and the blood-brain barrier. , 1986, Advances in neurology.